Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

PTGX holding history

Protagonist Therapeutics, Inc in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

PTGX overviewAll 13F holders of PTGXFull Q2 2026 holdings

Shares (Q2 2026)
3,399,221
Value
$416.7M
% of portfolio
0.1%
Quarters held
22
Since Q1 2021
Holdings of PTGX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20263,399,221$416.7M0.1%−1,778,575−34.4%ReducedHolders
Q1 20265,177,796$545.7M0.1%+2,407,775+86.9%AddedHolders
Q4 20252,770,021$241.9M<0.1%+874,013+46.1%AddedHolders
Q3 20251,896,008$126.0M<0.1%−605,243−24.2%ReducedHolders
Q2 20252,501,251$138.2M<0.1%+2,148,380+608.8%AddedHolders
Q1 2025352,871$17.1M<0.1%+220,262+166.1%AddedHolders
Q4 2024132,609$5.12M<0.1%+53,810+68.3%AddedHolders
Q3 202478,799$3.55M<0.1%+11,818+17.6%AddedHolders
Q2 202466,981$2.32M<0.1%−110,565−62.3%ReducedHolders
Q1 2024177,546$5.14M<0.1%+26,679+17.7%AddedHolders
Q4 2023150,867$3.46M<0.1%+60,141+66.3%AddedHolders
Q3 202390,726$1.51M<0.1%+25,186+38.4%AddedHolders
Q2 202365,540$1.81M<0.1%−50,399−43.5%ReducedHolders
Q1 2023115,939$2.67M<0.1%−109,590−48.6%ReducedHolders
Q4 2022225,529$2.46M<0.1%+178,949+384.2%AddedHolders
Q3 202246,580$393.0K<0.1%−82,407−63.9%ReducedHolders
Q2 2022128,987$1.02M<0.1%+6,222+5.1%AddedHolders
Q1 2022122,765$2.91M<0.1%+56,454+85.1%AddedHolders
Q4 202166,311$2.27M<0.1%−2,904−4.2%ReducedHolders
Q3 202169,215$1.23M<0.1%+66,544+2,491.4%AddedHolders
Q2 20212,671$120.0K<0.1%−41,902−94.0%ReducedHolders
Q1 202144,573$1.15M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.